Hofmann, H-S. and Ried, M. (2019) Hyperthermic intrathoracic chemotherapy in thoracic surgery. CHIRURG, 90 (8). pp. 681-694. ISSN 0009-4722, 1433-0385
Full text not available from this repository. (Request a copy)Abstract
In regional chemotherapy of the pleural space a differentiation is made between intrapleural hyperthermic perfusion (IHP) and hyperthermic intrathoracic chemotherapy (HITOC). The HITOC in particular is carried out as an additive procedure after surgical cytoreduction of the pleural tumor manifestation. The main indications are for malignant pleural mesothelioma and thymoma with pleural spread (stage IVa), whereas treatment of secondary pleural carcinomatosis is indicated only in selected patients suitable for resection followed by HITOC. Cisplatin is the standard chemotherapeutic agent and a concentration of 150-175mg/m(2) body surface area is recommended. Postoperative, HITOC-related complications (e.g. renal insufficiency) can be minimized by an adapted perioperative management. Safety measures should be accomplished adhered to for the protection of personnel. The aim of HITOC is to achieve a better local tumor control with a corresponding longer recurrence-free and overall survival.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MALIGNANT PLEURAL MESOTHELIOMA; CYTOREDUCTIVE SURGERY; EXTRAPLEURAL PNEUMONECTOMY; INTRAPLEURAL CHEMOTHERAPY; PHASE-II; CISPLATIN; PERFUSION; THYMOMA; PLEURECTOMY; CYTOPROTECTION; Regional chemotherapy; Cytoreduction; Malignant pleural mesothelioma; Thymoma; Pleural carcinomatosis |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Thoraxchirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 02 Apr 2020 05:15 |
| Last Modified: | 02 Apr 2020 05:15 |
| URI: | https://pred.uni-regensburg.de/id/eprint/26535 |
Actions (login required)
 |
View Item |
